Daiichi Sankyo Company, Limited (TYO: 4568) announced that DATROWAY (datopotamab deruxtecan), its TROP2-directed antibody drug conjugate (ADC) jointly developed and commercialized with AstraZeneca, has been approved in China for a new indication: the treatment of adult patients with unresectable or metastatic triple‑negative breast cancer (TNBC) who are not candidates for PD‑1/PD‑L1 inhibitor therapy. The approval by China’s National Medical Products Administration (NMPA) is based on the TROPION‑Breast02 phase 3 trial, in which DATROWAY significantly improved both median overall survival (23.7 vs. 18.7 months) and median progression‑free survival (10.8 vs. 5.6 months) versus investigator’s choice of chemotherapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New indication approval |
| Product | DATROWAY (datopotamab deruxtecan) – TROP2-directed ADC |
| Indication | Adult patients with unresectable or metastatic TNBC not candidates for PD‑1/PD‑L1 inhibitor therapy |
| Approval Date | 9 Oct 2026 (announced) |
| Pivotal Evidence | TROPION‑Breast02 phase 3 trial |
| Development & Commercialization | Discovered and developed on Daiichi Sankyo’s technology; jointly developed and commercialized by Daiichi Sankyo and AstraZeneca |
Drug Profile & Mechanism of Action
- Molecule: DATROWAY (datopotamab deruxtecan), an antibody drug conjugate built on Daiichi Sankyo’s proprietary ADC technology.
- Target: TROP2, a cell-surface antigen broadly expressed in epithelial cancers including triple‑negative breast cancer.
- Payload: A deruxtecan-family topoisomerase I inhibitor cytotoxic payload, delivered directly to TROP2-expressing tumor cells upon antibody binding and internalization.
- Modality Rationale: ADCs such as DATROWAY aim to concentrate potent chemotherapy at the tumor site, offering an alternative mechanism for patients ineligible for immunotherapy.
- Partnership: Discovered by Daiichi Sankyo; jointly developed and commercialized by Daiichi Sankyo and AstraZeneca under their global ADC collaboration.
Clinical Evidence – TROPION‑Breast02 Phase 3 Trial
| Endpoint | Result (DATROWAY) | Comparator (Investigator’s Choice of Chemotherapy) | Relative Benefit |
|---|---|---|---|
| Median Overall Survival (mOS) | 23.7 months | 18.7 months | +5.0 months (p=0.0291) |
| Median Progression‑Free Survival (mPFS) | 10.8 months | 5.6 months | +5.2 months; near doubling (p<0.0001) |
TROPION‑Breast02 was a phase 3 trial in patients with metastatic TNBC who are not candidates for PD‑1/PD‑L1 inhibitor therapy, comparing DATROWAY against investigator’s choice of chemotherapy. The study met its endpoints with statistically significant improvements in both overall survival and progression-free survival. Additional trial details — including patient numbers, sites, secondary endpoints, and safety data — were not disclosed in the announcement.
Disease & Treatment Context – TNBC
- Triple‑Negative Breast Cancer: TNBC lacks estrogen receptor, progesterone receptor, and HER2 expression, excluding patients from endocrine and HER2-targeted therapies and historically leaving chemotherapy as the mainstay of treatment.
- Aggressive Biology: TNBC is associated with earlier relapse and poorer prognosis relative to other breast cancer subtypes, with particularly limited options in the metastatic setting.
- The Immunotherapy-Ineligible Gap: For patients not candidates for PD‑1/PD‑L1 inhibitor therapy, treatment options have been especially constrained — the precise population addressed by this new China approval.
- TROP2 as a Validated Axis: TROP2-directed ADCs have emerged as a leading therapeutic strategy in heavily pretreated and immunotherapy-ineligible TNBC, with overall survival benefit of the magnitude seen in TROPION‑Breast02 representing a clinically meaningful advance.
Market Impact & Outlook
- China Market Expansion: The new NMPA indication extends DATROWAY’s China label into metastatic TNBC, opening access to a large patient population with high unmet need and limited alternatives.
- Partnership Economics: As a jointly developed and commercialized asset, DATROWAY’s China expansion contributes to the Daiichi Sankyo–AstraZeneca alliance economics; China launch timing, pricing, and reimbursement plans were not disclosed.
- Competitive Landscape: DATROWAY enters a TNBC ADC arena that includes other TROP2-directed and payload-differentiated conjugates; demonstrated mOS and mPFS superiority over chemotherapy positions it as a evidence-backed option in the immunotherapy-ineligible segment.
- Franchise Momentum: The approval adds to DATROWAY’s global regulatory footprint across tumor types, reinforcing Daiichi Sankyo’s standing in the ADC field built on its proprietary conjugation technology.
- Next Steps: Commercial rollout in China and any further indication or geography expansion were not detailed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding DATROWAY (datopotamab deruxtecan), including its commercialization in China for unresectable or metastatic TNBC, real-world effectiveness, and further regulatory expansions. Actual results may differ due to risks including reimbursement and pricing dynamics, competitive entry, real-world safety experience, and outcomes in additional trials. Trial data cited reflect the announced TROPION‑Breast02 results.-Fineline Info & Tech
